Compare HLI & FMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HLI | FMS |
|---|---|---|
| Founded | 1972 | 1996 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Investment Managers | Misc Health and Biotechnology Services |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4B | 14.1B |
| IPO Year | 2015 | 1996 |
| Metric | HLI | FMS |
|---|---|---|
| Price | $179.59 | $23.28 |
| Analyst Decision | Hold | Sell |
| Analyst Count | 9 | 2 |
| Target Price | ★ $205.38 | $30.00 |
| AVG Volume (30 Days) | 367.8K | ★ 482.1K |
| Earning Date | 10-30-2025 | 11-04-2025 |
| Dividend Yield | 1.34% | ★ 2.45% |
| EPS Growth | ★ 26.59 | 8.62 |
| EPS | ★ 6.19 | 2.86 |
| Revenue | $2,565,361,000.00 | ★ $23,046,819,198.00 |
| Revenue This Year | $15.23 | $2.12 |
| Revenue Next Year | $13.29 | $2.92 |
| P/E Ratio | $29.04 | ★ $15.86 |
| Revenue Growth | ★ 21.00 | 2.10 |
| 52 Week Low | $137.99 | $22.05 |
| 52 Week High | $211.78 | $30.46 |
| Indicator | HLI | FMS |
|---|---|---|
| Relative Strength Index (RSI) | 49.37 | 37.10 |
| Support Level | $171.77 | $22.51 |
| Resistance Level | $178.75 | $24.20 |
| Average True Range (ATR) | 3.98 | 0.30 |
| MACD | 1.22 | 0.09 |
| Stochastic Oscillator | 81.63 | 45.27 |
Houlihan Lokey Inc is an investment bank with expertise in mergers and acquisitions, capital markets, financial restructuring, valuation, and strategic consulting. The firm serves corporations, institutions, and governments world-wide with offices in the United States, Europe, and the Asia-Pacific region. The company operates in three segments. In the Corporate Finance business segment, it provides M&A and capital markets advisory services. Through the Financial Restructuring business segment, the company advises on some of the complex restructurings around the world. The Financial and Valuation Advisory Services business segment provides valuation and financial opinion, and financial and strategic consulting practices in the United States.
Fresenius Medical Care is the largest dialysis company in the world, treating about 300,000 patients from nearly 3,700 clinics worldwide as of December 2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.